Clinical Trials

27 enrolled

Hodgkin Disease

NCT03077828 2023-06-02

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

43 enrolled 9 charts

Hodgkin Disease

NCT04636255 2023-05-10

Physical Capacity in Hodgkin Lymphoma Survivors

Phase NA Unknown

40 enrolled

Cardiovascular Diseases, Hodgkin Disease

NCT05490953 2023-04-18

Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma

Phase 4 Unknown

Hodgkin Disease

NCT04981899 2023-04-12

NICE-40

Hodgkin Disease

NCT05772624 2023-03-16

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

16 enrolled

Hodgkin Disease

NCT05663983 2022-12-23

Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients

600 enrolled

Adolescent Behavior, Hodgkin Disease

NCT05660993 2022-12-21

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Disease

NCT05254821 2022-11-14

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients

130 enrolled

Hodgkin Disease

NCT02098512 2022-10-27

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Hodgkin Disease

NCT02589548 2022-05-17

Brazilian Prospective Hodgkin Lymphoma Registry

1,400 enrolled

Hodgkin Disease

NCT05284396 2022-03-17

Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs

Hodgkin Disease

NCT05225896 2022-02-07

CLIMDA

34 enrolled

Phase EARLY_PHASE1 Unknown

Hodgkin Disease

NCT05208853 2022-01-26

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

9 enrolled

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT04025424 2021-12-28

ICIPRESIST19

350 enrolled

DermatologicLymphoid

Uveal Melanoma, Hodgkin Disease, Melanoma

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

47 enrolled

Hodgkin Disease, Recurrence

NCT03374007 2021-08-16

GB226

72 enrolled

Hodgkin Disease, Lymphoma

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Hodgkin Disease

NCT00433433 2021-02-03

H10

Phase 3 Unknown

1,952 enrolled

Hodgkin Disease, Lymphoma

NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Phase NA Unknown

Hodgkin Disease

NCT04653649 2020-12-04

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Hodgkin Disease, Lymphoma, T-Cell

NCT00736320 2020-11-04

HD16

Phase 3 Unknown

1,150 enrolled

Hodgkin Disease

NCT03921879 2020-10-23

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT04419441 2020-09-16

ICI-RT-1

12 enrolled

Hodgkin Disease

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 2/3 Unknown

100 enrolled

Hodgkin Disease

NCT03474133 2020-07-21

BASALT

80 enrolled

Hodgkin Disease, Recurrence

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04024618 2020-03-31

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

Phase NA Unknown

40 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT01476410 2020-02-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

48 enrolled

Hodgkin Disease

NCT01619761 2020-02-11

NK Cells in Cord Blood Transplantation

LymphoidMyeloidOther hematologic neoplasm

13 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04239170 2020-01-23

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

84 enrolled

Hodgkin Disease

NCT03527628 2019-11-18

(Optimist)

220 enrolled

Hodgkin Disease

NCT03440788 2019-10-28

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

70 enrolled

Hodgkin Disease, Recurrence

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04026269 2019-07-19

Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen

Hodgkin Disease, Recurrence

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

280 enrolled

Hodgkin Disease, Recurrence

NCT01240525 2019-02-12

ProT4

LymphoidMyeloidOther hematologic neoplasmPlasma cell

114 enrolled

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Leukemia, Myelomonocytic, Juvenile

NCT03602131 2018-07-26

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03540849 2018-05-30

BV-ALLO

58 enrolled

Hodgkin Disease

NCT03315520 2018-05-22

BeEAC-1

100 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

72 enrolled

Hodgkin Disease, Recurrence

NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT03091933 2017-12-06

GLIDE

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03244930 2017-08-10

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies